Years of American investments in AIDS The programs have reduced the number of people killed by the disease to the lowest level for more than three decades and delivered for some of the strongest endangered of the worldwide life -saving medication.
In the past six months, the sudden payment of US money has caused a “systemic shock”, warned the UN officials and added that the financing, if not replaced, could lead to more than four million AIDS deaths and six million more HIV Infections by 2029.
“The current wave of financing losses has already destabilized the supply chains, led to the closure of health facilities, left thousands of health clinics without employees, resolved preventive programs, disturbed the HIV test efforts and forced many community organizations to reduce or stop their HIV activities in a report published on Thursday Thursday was released.
Unaids also said that she feared that other large donors could also reduce their support and that decades could reverse progress against AIDS worldwide – and that strong multilateral cooperation is in danger due to wars, geopolitical changes and climate change.
The 4 billion US dollars, which the United States promised for the Global HIV reaction for 2025, disappeared practically overnight in January when US President Donald Trump ordered that all foreign aid were exposed and later excluded the American aid agency.
Andrew Hill, an HIV expert at the University of Liverpool, who is not connected to the United Nations, said that Trump is entitled to spend US money, as he considers it right, “every responsible government would have given before warning so that the countries could plan” instead of increasing the patients in Africa, as clinics were closed overnight.
The emergency plan of the US President of AIDS relief or Pepper was launched in 2003 by US President George W. Bush, the greatest commitment of a country that focuses on a single illness.
Get weekly health news
Get the latest medical news and health information that will be made available to you every Sunday.
Unaids described the program as a “life vein” for countries with high HIV rates and said that, among other things, it tested tests for 84.1 million people, treatment of 20.6 million. According to data from Nigeria, Pepfar financed 99.9 percent of the country’s budget for medication to prevent HIV.
In 2024 there were around 630,000 AIDS deaths worldwide, according to an estimate by the UNAIDS-THE NAFE has been around the same since he had reached around 2 million deaths in 2004.
Before the US finance cuts, the progress against the containment of HIV was uneven. Unaids said that half of all new infections in Africa are south of the Sahara.
Tom Ellman from the charity without limits said that some poorer countries would now finance more of their own HIV programs, but it would be impossible to close the gap left by the USA
“We cannot do anything that will protect these countries from the sudden, malignant withdrawal of the support of the United States,” said Ellman, director of doctors without limits from South Africa Medical.
Experts also fear a different loss: data. The United States paid most HIV surveillance in African countries, including hospital, patient and electronics documents, which according to Dr. Chris Beyrer, director of the Global Health Institute of Duke University, have now been abruptly hired.
“Without reliable data about how HIV spreads, it will be incredibly difficult to stop it,” he said.
The uncertainty is a HIV injectable twice a year, as the studies published in the past year showed that the pharmaceutical manufacturer Gilead’s pharmaceutical process was 100% effective in preventing the virus.
At a starting event on Thursday, South African Minister of Health Aaron Motoaledi said that the country would “move mountains and rivers to ensure that every youthful girl who needs it will get,” and said that the dependency of the continent was “scary” by us.
Last month, the US Food and Drug Administration called the medication called Yeztugo, a step that should be a “threshold” for the end of the AIDS epidemic, said Peter Maybarduk from Advocacy Group Public Citizen.
But activists like Maybarduk said that Gilead’s prices will be out of reach in many countries who need it. Gilead has agreed to sell generic versions of the drug in 120 poor countries with high HIV rates, but almost all Latin America, where the tariffs are far lower, increases.
“We could end AIDS,” said Maybarduk. “Instead, the USA gives up the fight.”
& copy the Canadian press in 2025
